Seagen Inc. SGEN
At closeDec 13, 2023, 4:00 PM EST
52-week range unavailable
- Market cap
- 43.15B
- Revenue (ttm)
- 2.30B
- Profit margin
- -32.61%
- Shares out
- 188.66M
- Forward P/E
- -156.67
- Volume
- 19.39M
- Open
- 228.93
- Previous close
- 228.74
- Day's range
- 228.74 – 228.96
- Beta
- 0.32
- Analysts
- Buy
- Price target
- 229.00 (+0.1%)
- Earnings date
- Nov 1, 2023
2Y +71.96 (+45.90%)
Key statistics
- Enterprise value
- 42.04B
- PEG ratio
- 0.55
- Price / sales
- 18.76
- Price / book
- 16.92
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 27.10%
- Free cash flow
- -277.09M
- Total cash
- 1.24B
- Total debt
- 124.58M
- Return on equity
- -27.93%
- Short % of float
- 6.79%
- 50-day average
- 217.43
- 200-day average
- 204.65
Analyst view
Consensus: buy
- Strong buy3
- Buy5
- Hold8
- Sell0
- Strong sell0
Next earnings
Nov 1, 2023
Expected Nov 1, 2023. Consensus EPS estimate -1.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 1, 2023 | Sep 1, 2023 | -0.71 | — | — | — |
| Aug 2, 2023 | Jun 1, 2023 | -0.78 | — | — | — |
| Apr 27, 2023 | Mar 1, 2023 | -0.82 | — | — | — |
| Feb 15, 2023 | Dec 1, 2022 | -1.02 | — | — | — |
| Oct 27, 2022 | Sep 1, 2022 | -0.92 | — | — | — |
| Jul 28, 2022 | Jun 1, 2022 | -0.82 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 17, 2023 | Truist Securities | reit | Hold | Hold |
| Sep 24, 2023 | Truist Securities | reit | Hold | Hold |
| Aug 2, 2023 | Morgan Stanley | reit | Equal-Weight | Equal-Weight |
| Mar 23, 2023 | Berenberg | down | Buy | Hold |
| Mar 20, 2023 | TD Securities | main | — | Market Perform |
| Mar 19, 2023 | Truist Securities | main | — | Hold |
About Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- seagen.com
News
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen 
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb 
President Trump demands drugmakers slash prices within 60 days 
Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen 
Two Brothers, a Big Biotech Bet and an $8 Billion Payout 
Pfizer: Seagen Acquisition Starting To Bear Fruit 
Pfizer to close Seagen manufacturing plant in Seattle area following $43B acquisition 
Cramer names biopharma companies to watch as industry mergers start to pile up 
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 
5 Biotech Acquisition Targets To Accumulate In 2024
Your note
Sign in to keep a note on SGEN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | May 30, 2023 | 0 |
| DANSEY ROGER D | Officer | Sale | Sep 20, 2023 | 116,677 |
| EPSTEIN DAVID R | Chief Executive Officer | Sale | Nov 9, 2023 | 136,598 |
| GRYSKA DAVID W | Director | Stock Award(Grant) | May 30, 2023 | 51,047 |
| HIMES VAUGHN B | Chief Technology Officer | Sale | Nov 8, 2023 | 162,045 |
| LIU JEAN I | Officer | Sale | Sep 20, 2023 | 84,398 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Brothers Advisors, LLC | 23.74% | 44,554,162 | 8.57B | Jun 29, 2023 |
| Vanguard Group Inc | 7.09% | 13,315,658 | 2.56B | Jun 29, 2023 |
| Blackrock Inc. | 6.42% | 12,041,819 | 2.32B | Jun 29, 2023 |
| Pentwater Capital Management Lp | 5.13% | 9,629,500 | 1.85B | Jun 29, 2023 |
| Capital World Investors | 4.84% | 9,081,409 | 1.75B | Jun 29, 2023 |
| Capital International Investors | 3.42% | 6,417,224 | 1.24B | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Growth Fund Of America Inc | 3.52% | 6,610,163 | 1.27B | Jun 29, 2023 |
| Vanguard Total Stock Market Index Fund | 2.34% | 4,396,581 | 846.17M | Jun 29, 2023 |
| Vanguard Mid-Cap Index Fund | 1.74% | 3,259,531 | 627.33M | Jun 29, 2023 |
| Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 1.69% | 3,177,667 | 654.82M | Aug 30, 2023 |
| Vanguard Horizon Fund-Capital Opportunity Fund | 1.21% | 2,274,960 | 437.84M | Jun 29, 2023 |
| New Perspective Fund Inc | 1.20% | 2,260,964 | 435.15M | Jun 29, 2023 |